No 03 2016

Every successful region has a place where collaboration is allowed to take root and grow. A place that protects early ideas, carries learning forward, and helps people work together across borders even when the systems around them are not built for it. In Medicon Valley, many now share a simple vision: to create a kind of greenhouse for Nordic life science cooperation.

The Board of Directors of Spago Nanomedical has resolved on a new issue of shares with preferential rights for the company’s existing shareholders of approximately SEK 16 million before issue costs.

Sobi has announced positive topline results from the pivotal Phase 3 REDUCE 2 study evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.

The company has announced an investment led by HealthCap, and conjunction with this capital infusion, Neobiomics strengthens its board with the appointment of a new director, Mårten Steen, Managing Partner at HealthCap. 

Industry, academic, and public stakeholders will join forces in a new council aimed at accelerating the region's life science development.

Oncopeptides' clinical trial application for the "Window-of-Opportunity" (WoO) study in glioblastoma has been formally approved in Norway.

The orphan drug designation has been granted for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing’s disease.